AstraZeneca FY2026 EPS Forecast Raised by Leerink Partnrs

AstraZeneca PLC (NASDAQ:AZN) – Stock analysts at Leerink Partnrs boosted their FY2026 EPS estimates for shares of AstraZeneca in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst A. Berens now expects that the company will earn $6.08 per share for the year, up from their prior forecast of $6.05. The consensus estimate for AstraZeneca’s current full-year earnings is $4.12 per share.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the business posted $0.87 EPS. The company’s quarterly revenue was up 18.0% on a year-over-year basis.

A number of other equities analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 0.6 %

AstraZeneca stock opened at $68.60 on Wednesday. The firm has a 50-day moving average of $66.26 and a 200-day moving average of $74.28. AstraZeneca has a one year low of $60.47 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a market cap of $212.73 billion, a price-to-earnings ratio of 32.82, a P/E/G ratio of 1.13 and a beta of 0.46.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in AstraZeneca by 1.1% in the 3rd quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after acquiring an additional 258,477 shares during the period. Franklin Resources Inc. raised its holdings in AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after acquiring an additional 1,522,715 shares during the period. Fisher Asset Management LLC grew its position in shares of AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after purchasing an additional 524,175 shares in the last quarter. Manning & Napier Advisors LLC grew its position in shares of AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock worth $245,407,000 after purchasing an additional 564,297 shares in the last quarter. Finally, Clearbridge Investments LLC grew its position in shares of AstraZeneca by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.